CoChat

Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA

Wijarnpreecha, Karn, Kim, Donghee, Raymond, Pascale, Scribani, Melissa, Ahmed, Aijaz · 2019 · European Journal of Gastroenterology & Hepatology
Cited by 70

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background and aim: Nonalcoholic fatty liver disease (NAFLD) may be associated with sarcopenia. This study aims to determine whether sarcopenia is independently associated with NAFLD and advanced fibrosis. Participants and methods: Cross-sectional data from 11 325 participants in the third National Health and Nutrition Examination Survey were analyzed. NAFLD was defined as the presence of hepatic steatosis from the ultrasound. Sarcopenia was defined as the skeletal muscle index. Results: NAFLD was more common in participants with sarcopenia than in those without (46.7 vs. 27.5%). Univariate analysis showed that sarcopenia was associated with NAFLD [odds ratio (OR): 2.31; 95% confidence interval (CI): 2.01–2.64], which remained significant after adjustment for age, sex, ethnicity, metabolic risk factors (OR: 1.24; 95% CI: 1.03–1.48). This finding persisted after adjustment for C-reactive protein as a marker of chronic inflammation. NAFLD-associated advanced fibrosis was more common in participants with sarcopenia than in those without (7.8 vs. 1.6%). Sarcopenia was associated with NAFLD-associated advanced fibrosis independent of metabolic risk factors (OR: 1.79; 95% CI: 1.18–2.72). Conclusion: Sarcopenia was independently associated with increased odds of NAFLD and NAFLD-associated advanced fibrosis independent of well-defined risk factors. Interventions to strengthen muscle mass may reduce the burden of NAFLD and advanced fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/meg.0000000000001397

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 23

  1. Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes., Hepatology, 64, 73, 10.1002/hep.28431 · DOI · Paper page
  2. Non-alcoholic Fatty Liver Disease Study, 2015, Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups., Digest Liver Dis, 47, 997, 10.1016/j.dld.2015.08.004 · DOI · Paper page
  3. Byrne, 2015, NAFLD: a multisystem disease., J Hepatol, 62, S47, 10.1016/j.jhep.2014.12.012 · DOI · Paper page
  4. Janssen, 2011, The epidemiology of sarcopenia., Clin Geriatr Med, 27, 355, 10.1016/j.cger.2011.03.004 · DOI · Paper page
  5. Kim, 2014, Cardiometabolic implication of sarcopenia: The Korea National Health and Nutrition Examination Study (KNHANES) 2008–2010., IJC Metab Endocr, 4, 63, 10.1016/j.ijcme.2014.06.001 · DOI · Paper page
  6. Sinclair, 2016, Review article: sarcopenia in cirrhosis–aetiology, implications and potential therapeutic interventions., Aliment Pharmacol Ther, 43, 765, 10.1111/apt.13549 · DOI · Paper page
  7. Lee, 2015, Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008–2011)., J Hepatol, 63, 486, 10.1016/j.jhep.2015.02.051 · DOI · Paper page
  8. Lee, 2016, Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: nationwide surveys (KNHANES 2008–2011)., Hepatology, 63, 776, 10.1002/hep.28376 · DOI · Paper page
  9. Issa, 2014, Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis., Hepatology, 60, 428, 10.1002/hep.26908 · DOI · Paper page
  10. Petta, 2017, Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease., Aliment Pharmacol Ther, 45, 510, 10.1111/apt.13889 · DOI · Paper page
  11. Kim, 2017, Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States., PLoS One, 12, e0186702, 10.1371/journal.pone.0186702 · DOI
  12. Ruhl, 2005, Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population., Clin Gastroenterol Hepatol, 3, 1260, 10.1016/S1542-3565(05)00743-3 · DOI · Paper page
  13. Obisesan, 2012, Association of leisure-time physical activity with cognition by apolipoprotein-E genotype in persons aged 60 years and over: the National Health and Nutrition Examination Survey (NHANES-III)., Clin Interv Aging, 7, 35, 10.2147/CIA.S26794 · DOI
  14. Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD., Hepatology, 45, 846, 10.1002/hep.21496 · DOI · Paper page
  15. Foley, 2007, Kidney function and sarcopenia in the United States general population: NHANES III., Am J Nephrol, 27, 279, 10.1159/000101827 · DOI · Paper page
  16. 1994, Plan and Operation of the NHANES III, 1988–94, National Center for Health Statistics., Vital Health Stat, 1
  17. Musso, 2011, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity., Ann Med, 43, 617, 10.3109/07853890.2010.518623 · DOI · Paper page
  18. Belarmino, 2017, Phase angle obtained by bioelectrical impedance analysis independently predicts mortality in patients with cirrhosis., World J Hepatol, 9, 401, 10.4254/wjh.v9.i7.401 · DOI · Paper page
  19. Bhanji, 2017, Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in NASH., Hepatology, 66, 2055, 10.1002/hep.29420 · DOI · Paper page
  20. Kato, 2015, Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease., J Diabetes Investig, 6, 158, 10.1111/jdi.12271 · DOI · Paper page
  21. Ballestri, 2017, Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases., Metabolism, 72, 57, 10.1016/j.metabol.2017.04.003 · DOI · Paper page
  22. 2017, AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions., Dig Liver Dis, 49, 471, 10.1016/j.dld.2017.01.147 · DOI · Paper page
  23. Wong, 2018, Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: definition, risk factors and assessment., J Gastroenterol Hepatol, 33, 70, 10.1111/jgh.13857 · DOI · Paper page

Cited by

See all 70

Metadata

Authors
Wijarnpreecha, K., Kim, D., Raymond, P., Scribani, M., & Ahmed, A.
Venue
European Journal of Gastroenterology & Hepatology
Published
2019-09
Volume
31
Issue
9
Pages
1121-1128
ISSN
0954-691X (ISSN-L)
OpenAlex
W2924915225
Cited by
70
References
15
FWCI
5.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. https://app.cochat.ai/papers/10.1097/meg.0000000000001397
The paper
Wijarnpreecha, K., Kim, D., Raymond, P., Scribani, M., & Ahmed, A. (2019). Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. European Journal of Gastroenterology & Hepatology. https://doi.org/10.1097/meg.0000000000001397

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.